Literature DB >> 34253176

Depression and HIV associated neurocognitive disorders among HIV infected adults in rural southwestern Uganda: a cross-sectional quantitative study.

Jane Kasozi Namagga1, Godfrey Zari Rukundo2, Vallence Niyonzima3, Joachim Voss4.   

Abstract

BACKGROUND: HIV-Associated Neurocognitive Disorder (HAND remains a pronounced consequence of HIV/AIDS despite improved life expectancies. This is often associated with several dysfunctions such as decrease of attention, mood alterations and psychomotor disturbances. Many factors, including age, gender, employment status, and psychiatric disorders, have been associated with HAND. Among the associated psychiatric disorders, depression is often more prevalent. It can influence not only quality of life, relationships and employment but also adherence to medical care. We assessed the prevalence of depression and its association with HAND among people living with HIV in rural Southwestern Uganda.
METHODS: This was a cross-sectional study that used Beck Depression Inventory-1 and International HIV Dementia Scale to assess depression and HAND respectively. We defined depression with a score of > 10 and HAND with a cutoff score of ≤10. We conducted data analysis using STATA version 12, and Pearson Chi-square test and logistic regression to determine associations between depression and HAND. The level of statistical significance was set at p ≤ 0.05. Ethical approval and administrative clearance were obtained from relevant bodies.
RESULTS: Of the 393 participants assessed for depression and HAND, 27% had depression and 58.3% screened positive for HAND. All levels of depression were more prevalent among female participants. We found a significant association between depression and HIV associated neurocognitive disorders (χ2 (3) = 9.0538 p = 0.029).
CONCLUSION: Our findings confirmed a high prevalence of depression in individuals with HAND which is a major component of the disease burden.
© 2021. The Author(s).

Entities:  

Keywords:  Beck depression inventory-1; Depression; HIV-associated neurocognitive disorder; International HIV dementia scale

Year:  2021        PMID: 34253176     DOI: 10.1186/s12888-021-03316-w

Source DB:  PubMed          Journal:  BMC Psychiatry        ISSN: 1471-244X            Impact factor:   3.630


  30 in total

Review 1.  Human immunodeficiency virus-associated dementia: an evolving disease.

Authors:  Justin C McArthur; Norman Haughey; Suzanne Gartner; Kathy Conant; Carlos Pardo; Avi Nath; Ned Sacktor
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

2.  Updated research nosology for HIV-associated neurocognitive disorders.

Authors:  A Antinori; G Arendt; J T Becker; B J Brew; D A Byrd; M Cherner; D B Clifford; P Cinque; L G Epstein; K Goodkin; M Gisslen; I Grant; R K Heaton; J Joseph; K Marder; C M Marra; J C McArthur; M Nunn; R W Price; L Pulliam; K R Robertson; N Sacktor; V Valcour; V E Wojna
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

3.  Depression symptoms, social support and overall health among HIV-positive individuals in Kenya.

Authors:  Caroline Kingori; Zelalem T Haile; Peter Ngatia
Journal:  Int J STD AIDS       Date:  2014-04-22       Impact factor: 1.359

4.  Identifying risk factors for HIV-associated neurocognitive disorders using the international HIV dementia scale.

Authors:  Sara Cross; Nur Önen; Amber Gase; Edgar Turner Overton; Beau M Ances
Journal:  J Neuroimmune Pharmacol       Date:  2013-10-10       Impact factor: 4.147

5.  Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study.

Authors:  J R Ickovics; M E Hamburger; D Vlahov; E E Schoenbaum; P Schuman; R J Boland; J Moore
Journal:  JAMA       Date:  2001-03-21       Impact factor: 56.272

Review 6.  The end of AIDS: HIV infection as a chronic disease.

Authors:  Steven G Deeks; Sharon R Lewin; Diane V Havlir
Journal:  Lancet       Date:  2013-10-23       Impact factor: 79.321

7.  Depression and patterns of self-reported adherence to antiretroviral therapy in Rwanda.

Authors:  Emily B Wroe; Bethany L Hedt-Gauthier; Molly F Franke; Sabin Nsanzimana; Jean Bosco Turinimana; Peter Drobac
Journal:  Int J STD AIDS       Date:  2014-05-14       Impact factor: 1.359

8.  Two-year prospective study of major depressive disorder in HIV-infected men.

Authors:  J Hampton Atkinson; Robert K Heaton; Thomas L Patterson; Tanya Wolfson; Reena Deutsch; Stephen J Brown; J Summers; A Sciolla; R Gutierrez; Ronald J Ellis; Ian Abramson; John R Hesselink; J Allen McCutchan; Igor Grant
Journal:  J Affect Disord       Date:  2007-11-28       Impact factor: 4.839

9.  Depressive symptoms and neurocognitive performance among HIV-infected women.

Authors:  Renata Margalho Fialho; Marco Pereira; Nuno Mendonça; Sílvia Ouakinin
Journal:  Women Health       Date:  2013

Review 10.  A systematic review of the screening accuracy of the HIV Dementia Scale and International HIV Dementia Scale.

Authors:  Lewis John Haddow; Sian Floyd; Andrew Copas; Richard John Cary Gilson
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

View more
  3 in total

1.  Mbarara University Research Training Initiative: Experiences and Accomplishments of the MEPI Junior D43 TW010128 Award in Uganda.

Authors:  Edith K Wakida; Clara D Atuhaire; Christine K Karungi; Samuel Maling; Celestino Obua
Journal:  Adv Med Educ Pract       Date:  2021-12-03

2.  Peripheral inflammation and depressed mood independently predict neurocognitive worsening over 12 years.

Authors:  Bin Tang; A C Collier; S Morgello; D Cookson; N Sacktor; Ronald J Ellis; Christina M Marra; David B Clifford; Benjamin B Gelman; Jessica Robinson-Papp; J Allen McCutchan; Scott Letendre; Robert K Heaton; Igor Grant
Journal:  Brain Behav Immun Health       Date:  2022-03-10

Review 3.  Sirtuins Modulation: A Promising Strategy for HIV-Associated Neurocognitive Impairments.

Authors:  Izchel Figarola-Centurión; Martha Escoto-Delgadillo; Gracia Viviana González-Enríquez; Juan Ernesto Gutiérrez-Sevilla; Eduardo Vázquez-Valls; Blanca Miriam Torres-Mendoza
Journal:  Int J Mol Sci       Date:  2022-01-07       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.